346 related articles for article (PubMed ID: 31021438)
1. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
Sbidian E; Billionnet C; Weill A; Maura G; Mezzarobba M
Br J Dermatol; 2020 Mar; 182(3):690-697. PubMed ID: 31021438
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
[TBL] [Abstract][Full Text] [Related]
4. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
6. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
Armstrong A; Levi E
J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
[TBL] [Abstract][Full Text] [Related]
7. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
[TBL] [Abstract][Full Text] [Related]
8. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting.
Kapniari E; Dalamaga M; Papadavid E
Dermatol Ther; 2020 Nov; 33(6):e14168. PubMed ID: 32779293
[TBL] [Abstract][Full Text] [Related]
9. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
10. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
Distel J; Cazzaniga S; Seyed Jafari SM; Emelianov V; Schlapbach C; Yawalkar N; Heidemeyer K
Dermatology; 2022; 238(2):267-275. PubMed ID: 34091455
[TBL] [Abstract][Full Text] [Related]
12. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
Poulin Y; Beauchemin C; Royer C; Gaudreau AJ; Yim C; Liu FF; Lachaine J
J Cutan Med Surg; 2020; 24(6):573-587. PubMed ID: 32597685
[TBL] [Abstract][Full Text] [Related]
13. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland.
Koskivirta I; Ruotsalainen J; Kurki S; Lakkakorpi P; Salminen-Mankonen H; Pirilä L; Harvima R; Palomäki A
Scand J Rheumatol; 2023 Sep; 52(5):549-555. PubMed ID: 36644971
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
Ohata C; Ohyama B; Kuwahara F; Katayama E; Nakama T
J Dermatolog Treat; 2019 Jun; 30(4):383-386. PubMed ID: 30221571
[No Abstract] [Full Text] [Related]
15. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
16. Real-World Experience With Apremilast in Treating Psoriasis.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
[TBL] [Abstract][Full Text] [Related]
17. Apremilast in psoriasis - a prospective real-world study.
Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
[TBL] [Abstract][Full Text] [Related]
18. Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink.
Persson R; Cordey M; Paris M; Jick S
Drug Saf; 2022 Nov; 45(11):1403-1411. PubMed ID: 36151359
[TBL] [Abstract][Full Text] [Related]
19. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]